AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00065351
Drug: CC-5013
RxNorm normalized name: CC
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CC-5013 - oral - 30mg daily on days 1-21 every 28 days
Trial: NCT00278967
Drug: HalfLytely with Bisacodyl Tablets Bowel Prep Kit
RxNorm normalized name: bisacodyl
DrugBank: Bisacodyl (DB09020)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00123903
Drug: metoprolol xl
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00123903
Drug: carvedilol MR
RxNorm normalized name: Carvedilol
DrugBank: Carvedilol (DB01136)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00123903
Drug: lisinopril
RxNorm normalized name: Lisinopril
DrugBank: Lisinopril (DB00722)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04282824
Drug: Gallium Ga 68-labeled PSMA-11
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium nitrate (DB05260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05296213
Drug: Silver diamine fluoride- potassium iodide
RxNorm normalized name: silver fluoride
DrugBank: Potassium Iodide (DB06715)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SDF-KI (riva star, SDI.Ltd )was applied ( as a professional application) by micro brush over the early enamel lesions on the buccal surface of molar teeth
Trial: NCT05296213
Drug: Casein phosphopeptide amorphous calcium phosphate
RxNorm normalized name: caseins
DrugBank: Casein (DB10516)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPP-ACP (tooth mousse, GC, Matraville Sydney, Australia) was applied by using micro brush over the early enamel lesions on the buccal surface of the molar teeth twice daily. the patients were instructed to leave it for about 3minutes before rinsing
Trial: NCT00338650
Drug: adalimumab
RxNorm normalized name: Adalimumab
DrugBank: Adalimumab (DB00051)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT04522466
Drug: Hydroxychloroquine (HCQ)
DrugBank: Hydroxychloroquine (DB01611)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydroxychloroquine (HCQ) will be administered as usual practice: dosage is adjusted to maintain a concentration between 1 and 2 mg/L.~Measure pharmacokinetics and pharmacodynamics of Hydroxychloroquine (HCQ).
Trial: NCT00957060
Drug: GLIMEPIRIDE (HOE490)
RxNorm normalized name: Glimepiride
DrugBank: Glimepiride (DB00222)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: 2 mg and 4 mg tablets Route of administration: oral
Trial: NCT00957060
Drug: SITAGLIPTIN
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: 100 mg tablets Route of administration: oral
Trial: NCT03643276
Drug: Blinatumomab
RxNorm normalized name: Blinatumomab
DrugBank: Blinatumomab (DB09052)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Experimental therapy in randomizations R-HR and R-MR
Trial: NCT03643276
Drug: Bortezomib
RxNorm normalized name: Bortezomib
DrugBank: Bortezomib (DB00188)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Experimental therapy in randomization R-eHR
Trial: NCT03643276
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T and in the intensification block Myocet-FLA for patients with very high relapse risk
Trial: NCT03643276
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of standard chemotherapy
Trial: NCT03643276
Drug: Myocet
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk
Trial: NCT03643276
Drug: Dexamethasone
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone (DB01234)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of standard chemotherapy
Trial: NCT03643276
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Part of standard chemotherapy
Trial: NCT03643276
Drug: Fludarabine Phosphate
RxNorm normalized name: Fludarabine Phosphate
DrugBank: Fludarabine (DB01073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of intensification block Myocet-FLA for patients with very high relapse risk
Trial: NCT03643276
Drug: Ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of standard chemotherapy
Trial: NCT03643276
Drug: 6-Mercaptopurine
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of standard chemotherapy and included in experimental treatment phase Protocol IB long in randomization R-T
Trial: NCT03643276
Drug: Pegaspargase
RxNorm normalized name: pegaspargase
DrugBank: Pegaspargase (DB00059)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of standard chemotherapy
Trial: NCT03643276
Drug: Tioguanin
RxNorm normalized name: Tioguanin
DrugBank: Tioguanine (DB00352)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part of standard chemotherapy
Trial: NCT03643276
Drug: Vincristine
RxNorm normalized name: Vincristine
DrugBank: Vincristine (DB00541)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Part of standard chemotherapy
Trial: NCT03643276
Drug: Vindesine
RxNorm normalized name: vindesine
DrugBank: Vindesine (DB00309)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part of standard chemotherapy
Trial: NCT03643276
Drug: Erwinase
RxNorm normalized name: Erwinase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part of standard chemotherapy as substitute for PEG-L-Asparaginase in case of allergic reaction
Trial: NCT03990922
Drug: Patient-controlled analgesia with morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Morphine given as intravenous patient-controlled analgesia bolus: 2mg, lock time: 5min, 1h limitation: 8mg
Trial: NCT01116128
Drug: dasatinib
RxNorm normalized name: Dasatinib
DrugBank: Dasatinib (DB01254)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100 mg QD continuously (from day 1 to day 28)
Trial: NCT01116128
Drug: melphalan
RxNorm normalized name: Melphalan
DrugBank: Melphalan (DB01042)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0,18 mg/Kg/day from day 1 to day 4 for 6 cycles
Trial: NCT01116128
Drug: prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1,5 mg/Kg/day from day 1 to day 4 for 6 cycles
Trial: NCT01646151
Drug: Bimatoprost
RxNorm normalized name: Bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Bimatoprost-containing eye drops administered in the affected eye(s) at a dose determined by the physician in accordance with standard of care for up to 12 weeks.
Trial: NCT00928902
Drug: low-dose IL-2
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: low-dose IL-2, administered daily for 6 weeks, to begin either at week 1 (group 1) or week 4 (group 2)
Trial: NCT01436526
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single oral dose of rivaroxaban administered under fasting conditions 2\*5 mg tablet in first intervention period and 1\*10 mg tablet in second intervention period (after washout period)
Trial: NCT01436526
Drug: Rivaroxaban (Xarelto, BAY59-7939)
RxNorm normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Single oral dose of rivaroxaban administered under fasting conditions 1\*10 mg tablet in first intervention period and 2\*5 mg tablet in second intervention period (after washout period)
Trial: NCT00395746
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide 0.6 mg/day or placebo. Injected s.c. (under the skin) once daily.
Trial: NCT00395746
Drug: liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide 0.9 mg/day or placebo. Injected s.c. (under the skin) once daily.
Trial: NCT03818399
Drug: SUBLOCADE
RxNorm normalized name: Sublocade
DrugBank: Buprenorphine (DB00921)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: SUBLOCADE (buprenorphine extended-release) injection is a colorless to amber sterile solution for SC injection designed to deliver buprenorphine at doses of 100 mg or 300 mg at a controlled rate over a one-month period.
Trial: NCT03515577
Drug: Fluciclovine F18
RxNorm normalized name: FLUCICLOVINE F18 (9-221 MCI/ML) INJ
DrugBank: Fluciclovine (18F) (DB13146)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given fluciclovine F18
Trial: NCT03515577
Drug: Gallium Ga 68-labeled PSMA-11
RxNorm normalized name: Ga-68-Labeled PSMA-11
DrugBank: Gallium nitrate (DB05260)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT00441298
Drug: Tenofovir gel
RxNorm normalized name: Tenofovir
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will be provided with a supply of single-use, pre-filled applicators according to their randomisation. While in the study, participants will be asked to apply a first dose of the assigned study product, 1% tenofovir gel, within 12 hours prior to coitus and insert a second dose as soon as possible within 12 hours after coitus. They will be advised to use only two doses of gel in a 24-hour period.
Trial: NCT01065506
Drug: Nicotine Patch
RxNorm normalized name: Nicotine Patch
DrugBank: Nicotine (DB00184)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nicotine Patch
Trial: NCT00989469
Drug: Nexavar (Sorafenib) and irinotecan (Campto)
RxNorm normalized name: Nexavar
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sorafenib administrated continuously orally 400 mg twice daily (a daily total dose of 800 mg). Irinotecan 180 mg/m² will be administered IV for 90 minutes every 2 weeks. The first dose of sorafenib will be administered after the first perfusion of irinotecan 180 mg/m² at the first infusion
Trial: NCT00934791
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tacrolimus 6-10 mg/day (maintain trough levels of 8-10 ng/mL)
Trial: NCT00934791
Drug: Sirolimus
RxNorm normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Sirolimus 3-5 mg/day (maintain high-performance liquid chromatography (HPLC) blood level 10-15 ng/mL)
Trial: NCT00934791
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate Mofetil 750 mg twice daily
Trial: NCT00934791
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prednisone tapered to 5 mg/day by day 92
Trial: NCT00162799
Drug: Triflusal (DCI)
RxNorm normalized name: triflusal
DrugBank: Triflusal (DB08814)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00765830
Drug: vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 50mg qd
Trial: NCT01310985
Drug: Capecitabine (Xelodaâ), XRT & Cetuximab (Erbitux®)
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Capecitabine (Xelodaâ), External Beam Radiation and Cetuximab (Erbitux®)
Trial: NCT00043966
Drug: Lopinavir/ritonavir
RxNorm normalized name: LOPINAVIR/RITONAVIR
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00043966
Drug: Tenofovir DF
RxNorm normalized name: LAMIVUDINE 300MG/TENOFOVIR DF 300MG TAB
DrugBank: Tenofovir (DB14126)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00043966
Drug: Emtricitabine
RxNorm normalized name: Emtricitabine
DrugBank: Emtricitabine (DB00879)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00723515
Drug: sodium fluoride
RxNorm normalized name: Sodium Fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: sodium fluoride 5%
Trial: NCT01304927
Drug: Cholecalciferol and calcium
RxNorm normalized name: Cholecalciferol
DrugBank: Cholecalciferol (DB00169)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Initial one dose oral mixture of 300.000 IU Cholecalciferol followed by 5 months treatment with one tablet daily containing 35 ug Cholecalciferol and 500 mg calcium
Trial: NCT02144662
Drug: Ranibizumab
RxNorm normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 0.5mg ranibizumab intravitreal injection
Trial: NCT02825641
Drug: Oxytocin
RxNorm normalized name: Oxytocin
DrugBank: Oxytocin (DB00107)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Labor induction and cervical ripening by oxytocin in women with premature rupture of membranes in 2 types of women:~1. Induction of labor on presentation at the delivery room.~2. Induction of labor after 24 hours of rupture of membranes.
Trial: NCT00552201
Drug: Tacrolimus
RxNorm normalized name: Tacrolimus
DrugBank: Tacrolimus (DB00864)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administration Twice a day after adjustment to blood level
Trial: NCT00914095
Drug: methylphenidate
RxNorm normalized name: Methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg tablet of methylphenidate 3 times a day (1 mg/kg/day)
Trial: NCT01602640
Drug: Morphine infusion
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventional dose
Trial: NCT03898024
Drug: SHR-1222
RxNorm normalized name: SHR-A1904
DrugBank: SHR-A1904 (DB18702)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: water injection; Route of administration: subcutaneous
Trial: NCT02200094
Drug: Low dose of Telmisartan, once daily
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03062813
Drug: Tacrolimus &entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus (0.05-0.1 mg/kg/day) combined with entecavir. Tacrolimus was divided into two daily doses at 12-hour intervals. Subsequent doses were adjusted to achieve a whole blood 12-hour trough level between 5 and 10 ng/ml.All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
Trial: NCT03062813
Drug: placebo & entecavir
DrugBank: Entecavir (DB00442)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: HBV-GN patients with nephrotic syndrome were randomly givenTacrolimus placebo (0.05-0.1 mg/kg/day) combined with entecavir.Tacrolimus placebo was divided into two daily doses at 12-hour intervals. All patients will receive entecavir antiviral therapy(0.5mg/d), entecavir was taken once a day. All of HBV-GN patients were followed up to 25week.
Trial: NCT00696540
Drug: Inhalation of salbutamol diluted in normal saline
RxNorm normalized name: NS-2359
DrugBank: NS-2359 (DB05805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The 3 nebulizations of 0.5 mg of Salbutamol are diluted in 3.5 ml of normal (0.9%) saline.
Trial: NCT03709940
Drug: MPH
RxNorm normalized name: MPH
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants undergo behavioural tests and brain scanning twice, once under placebo and once under an acute dose of MPH, before starting long-term treatment with a long-acting formulation of MPH used routinely at the Adult ADHD Clinic.
Trial: NCT02479217
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02479217
Drug: Xeloda
RxNorm normalized name: Xeloda
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02400840
Drug: gadobenic acid intravenous injection 0.2 ml/kg
DrugBank: Gadobenic acid (DB00743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gadobenic acid intravenous injection 0.2 ml/kg is used one time for cardiac MRI assessment
Trial: NCT00703820
Drug: Cytarabine
RxNorm normalized name: Cytarabine
DrugBank: Cytarabine (DB00987)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Detailed Description
Trial: NCT00703820
Drug: Daunorubicin
RxNorm normalized name: daunorubicin
DrugBank: Daunorubicin (DB00694)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Detailed Description
Trial: NCT00703820
Drug: Etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: See Detailed Description
Trial: NCT00703820
Drug: Clofarabine
RxNorm normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: See Detailed Description
Trial: NCT02532998
Drug: Fludrocortisone, tablets
DrugBank: Fludrocortisone (DB00687)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose of 0.5 mg and maintenance doses of 0.1 mg every second hour up to a total dose of 1.0 mg per treatment period (may be modified to up to 1.3 mg based on emerging data)
Trial: NCT00005066
Drug: O6-benzylguanine
RxNorm normalized name: O6-benzylguanine
DrugBank: 6-O-benzylguanine (DB11919)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00005066
Drug: carmustine
RxNorm normalized name: Carmustine
DrugBank: Carmustine (DB00262)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00004885
Drug: irinotecan hydrochloride
RxNorm normalized name: Irinotecan Hydrochloride
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03639896
Drug: Dexmedetomidine
RxNorm normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 0.5μg/kg Dexmedetomidine as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
Trial: NCT03639896
Drug: Saline
RxNorm normalized name: Salinex
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.5μg/kg saline as initial loading dose is given for 15 minutes before induction of anesthesia, followed by a maintenance infusion of 0.4μg/kg/h and stopped 30 minutes before the surgery over.
Trial: NCT04265027
Drug: 50 mg Ongentys
RxNorm normalized name: opicapone 50 MG [Ongentys]
DrugBank: Opicapone (DB11632)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Hard Capsule; Oral
Trial: NCT04265027
Drug: 25 mg Ongentys
RxNorm normalized name: opicapone 25 MG [Ongentys]
DrugBank: Opicapone (DB11632)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Hard Capsule; Oral
Trial: NCT03172234
Drug: oral gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: In gabapentin group: the patients will receive oral 800 mg gabapentin 90 minute prior to the surgery
Trial: NCT04006821
Drug: PD-1 antibody
RxNorm normalized name: Anti-PD-1 monoclonal antibody MGA012
DrugBank: Retifanlimab (DB15766)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Camrelizumab will be administered 200mg iv every 2 weeks until disease progression or lasts for two years.
Trial: NCT04006821
Drug: Apatinib mesylate
RxNorm normalized name: mesylate
DrugBank: Rivoceranib (DB14765)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apatinib mesylate will be administered 250mg or 500mg (according to the patient's tolerance), qd, oral, until disease progression.
Trial: NCT01020643
Drug: controlled administration of propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: comparison of propofol sedation
Trial: NCT00826787
Drug: Levetiracetam
RxNorm normalized name: Levetiracetam
DrugBank: Levetiracetam (DB01202)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 750 mg tablet
Trial: NCT01426009
Drug: EP-101 via nebulizer (eFlow®) 100 ug
RxNorm normalized name: Ep-100 (peptide)
DrugBank: Onvitrelin ucalontide (DB19183)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EP-101 (100ug) administered once daily for 7 days
Trial: NCT01426009
Drug: Tiotropium bromide via (Spiriva® Handihaler®)
RxNorm normalized name: Tiotropium Bromide
DrugBank: Tiotropium (DB01409)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tiotropium 18 µg administered once daily for 7 days using Handihaler® DPI
Trial: NCT01426009
Drug: Ipratropium bromide Inhalation Solution via Handihaler® DPI
DrugBank: Ipratropium (DB00332)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ipratropium 500 µg administered three times daily for 7 days using general purpose nebulizer
Trial: NCT02308319
Drug: Tenofovir disoproxil fumarate
RxNorm normalized name: Tenofovir Disoproxil Fumarate
DrugBank: Tenofovir disoproxil (DB00300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 300mg q.d. per oral
Trial: NCT02612233
Drug: Pregabalin or Duloxetine or Placebo
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Pregabalin (DB00230)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: This is a randomized, double blind placebo controlled trial with a head-to-head comparison of duloxetine vs pregabalin vs placebo over-encapsulated to prevent unblinding of treatment arm
Trial: NCT00175838
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (or hydroxycarbamide) is an antineoplastic drug commonly used to treat haematological malignancies.
Trial: NCT00175838
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin is an anti-aggregating agent, and has been shown to reduce/alleviate minor ischaemic symptoms.
Trial: NCT00068549
Drug: Gemcitabine Hydrochloride
RxNorm normalized name: Gemcitabine Hydrochloride
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV
Trial: NCT00068549
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV